Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.49 |
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | CETP | P11597 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methylamine SCHEMBL28245020 | 0.98 | MAPT (0.56) | MAPTKMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL19766698 | 0.85 | MAPT (0.62) | MAPTKMT2AMEN1POLBSMN1; SMN2 | |
| SCHEMBL11893003 | 0.83 | KMT2A (0.60) | MAPTKMT2AMEN1POLBSMN1; SMN2 | |
| SCHEMBL15413796 | 0.82 | MAPK1 (0.50) | MAPTKMT2AMEN1L3MBTL1SMN1; SMN2 | |
| SCHEMBL28864966 | 0.82 | LMNA (0.47) | MAPTKMT2AMEN1POLBL3MBTL1 | |
| SCHEMBL15798428 | 0.81 | MAPT (0.58) | MAPTKMT2AMEN1POLBSMN1; SMN2 | |
| SCHEMBL5236602 | 0.81 | MAPT (0.58) | MAPTKMT2AMEN1POLBSMN1; SMN2 | |
| SCHEMBL29620186 | 0.81 | MAPT (0.58) | MAPTKMT2AMEN1POLBSMN1; SMN2 | |
| SCHEMBL29625776 | 0.81 | MAPT (0.58) | MAPTKMT2AMEN1POLBSMN1; SMN2 | |
| SCHEMBL19610235 | 0.81 | MAPT (0.58) | MAPTKMT2AMEN1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107235842-B | Phenylpropanoate derivative and preparation method and application thereof | 西安科技大学 | 2021-02-26 | — | — | CN | disclosed |
| EP-3071562-B1 | TETRAHYDRO-BENZODIAZEPINONES | HOFFMANN LA ROCHE (CH) | 2020-10-14 | — | — | EP | disclosed |
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| CN-106029650-B | Tetrahydro-benzodiazepine * ketone | 豪夫迈·罗氏有限公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-104470940-B | The purposes of 2- oxos -2,3,4,5- tetrahydrochysene -1H- benzos [b] [Isosorbide-5-Nitrae] diaza * and its treating cancer | 霍夫曼-拉罗奇有限公司 | 2018-10-16 | — | — | CN | disclosed |
| US-10053431-B2 | Tetrahydro-benzodiazepinones | HOFFMANN-LA ROCHE INC. (US) | 2018-08-21 | — | — | US | disclosed |
| CN-104470905-B | The miscellaneous azepine * assimilation compounds of substitution | 霍夫曼-拉罗奇有限公司 | 2017-09-12 | — | — | CN | disclosed |
| CN-104507913-B | The antiproliferative ketone of benzo [b] azepine * 2 | 霍夫曼-拉罗奇有限公司 | 2017-07-28 | — | — | CN | disclosed |
| EP-2897972-B1 | 2-OXO-2,3,4,5-TETRAHYDRO-1H-BENZO[B]DIAZEPINES AND THEIR USE IN THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2016-11-30 | — | — | EP | disclosed |
| CN-106029650-A | Tetrahydro-benzodiazepinones | 豪夫迈·罗氏有限公司 | 2016-10-12 | — | — | CN | disclosed |
| US-5612368-A | SKIN DISORDERS, MELATONINERGIC SYSTEMS, ANTIARRHYTHMIA AGENTS OR ANTIISCHEMIC AGENTS | ADIR ET COMPAGNIE (FR) | 1997-03-18 | — | — | US | disclosed |
| US-5604261-A | HAVING HYDROXYL/ALKOXYL GROUP ORTHO TO AMIDE GROUP ON PHENYL RING; HIGH MELATONIN RECEPTOR AFFINITY | ADIR ET COMPAGNIE (FR) | 1997-02-18 | — | — | US | disclosed |
| US-5578634-A | SEPTIC SHOCK TREATMENT | ELI LILLY AND COMPANY (US) | 1996-11-26 | — | — | US | disclosed |
| US-5554642-A | USE TO TREAT MAMMALS AFFLICTED WITH SLEEP DISORDERS | ADIR ET COMPAGNIE (FR) | 1996-09-10 | — | — | US | disclosed |
| CN-1127247-A | New o-arylmethyl-N-(thio)acylhydroxylamines, process for preparing them and pharmaceutical compositions containing them | ADIR (FR) | 1996-07-24 | — | — | CN | disclosed |
| EP-0591057-B1 | Arylalkyl(thio)amides with melatonine receptor selectivity and process for their preparation | ADIR (FR) | 1996-07-10 | — | — | EP | disclosed |
| US-5464872-A | Sleep disorders | ADIR ET COMPAGNIE (FR) | 1995-11-07 | — | — | US | disclosed |
| CN-1098714-A | The 1H-indole-3-acetic acid hydrazide spla 2 inhibitors | LILLY CO ELI (US) | 1995-02-15 | — | — | CN | disclosed |
| EP-0620214-A1 | 1H-indole-3-acetic acid hydrazide sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 1994-10-19 | — | — | EP | disclosed |
| EP-0591057-A1 | Arylalkyl(thio)amides with melatonine receptor selectivity and process for their preparation | ADIR ET COMPAGNIE (FR) | 1994-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10053431-B2 | Tetrahydro-benzodiazepinones | GABBR1, TPH1, GABBR2 | MAPT 2980/4885KMT2A 1452/4885MEN1 1123/4885 |
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | NR1H2, NR1H3, NR1H4 | MAPT 3356/4885KMT2A 1448/4885MEN1 4789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.